In 1902, first conference called by Belgian government and held in Brussels, resulted in the agreement for the unification of formula of potent drugs, which was ratified in 1906 by 19 countries. These outcomes considerably influenced the subsequent publication of national pharmacopoeias. The second editions of international pharmacopeia were published in 1967 and specification for the quality control (QC) of pharmaceutical preparation was classified in it.

The drug regulation process made a breakthrough during the 19^th^ century and laid a strong foundation for modern research and development. However, the thalidomide disaster in 1956 gave a newer direction in order to incorporate stringent measures for safety of drug.

In the year 1962, Food and Drug Administration (FDA) approved for the 1^st^ time the concept of efficacy along with safety for new drug application (NDA), through Kefauver-Harris amendment, which revolutionized the drug development. During the same year FDA was also given authority to require compliance with good manufacturing practice (GMP) and good laboratory practice (GLP) regulations. The pharmaceutical industry is regulated by GMP and GLP in order to minimize the risks that might have an impact on the quality and reproducibility of pharmaceutical products. The purpose of these regulations is to assure that pharmaceutical product must meet the safety requirements in order to have intended product identity and purity characteristics.

The GMP and current GMP provide a system that assures proper design, monitoring and control of manufacturing processes and facilities. This includes establishing a strong quality management system, obtaining appropriate quality raw material, establishing robust operational procedure, detection of product quality deviation and maintaining of reliable testing laboratories.

In 1989, international conference of drug regulatory authorities organized by World health organization in Paris revealed the need for harmonization of requirements, which lead to the establishment of registration of pharmaceuticals for human use (ICH) in 1990.

Traditionally, pharmaceutical companies have been focusing on the combination of quality assurance and QC approach. However, quality management is the latest concept and involves a broader platform to ensure quality by "bottom-up" approach.

Quality by design (QBD) is customized and a latest version of quality management system in pharma sector. It covers "QBD" of pharma products by designing, development of formulation and various manufacturing processes to predefined product quality. From January 2013 onward QBD became mandatory requirements for filling NDAs. Implementation of QBD by various regulatory authorities will contribute the information inputs to be included in regulatory filling. In consonance with these guidelines, FDA emphasized on scientific principles of risk based processes, product development and commercialization, which are underlined in ICH Q8 for pharmaceutical development, ICH Q9 for quality risk management, ICH Q10 for pharmaceutical quality system.

Looking at the development stages and the evolution process, we can clearly see a significant progress in understanding the concept of quality of the drugs and drug products. There is a sufficient clarity in the role of multivariate variables that contribute to quality attributes, the role of "dose efficacy," "deliverability" of difficult drugs and many other factors, which can envisage specific and predetermined outcomes from inactive and active medicaments.
